key: cord-0920637-zywl1nnj
authors: Moreno‐Pérez, Oscar; Ramos, Jose Manuel; Gimeno, Adelina; Rodríguez, Juan Carlos; Andres, Mariano; Leon‐Ramirez, Jose‐Manuel; Valero, Beatriz; Llorens, Pere; Boix, Vicente; Gil, Joan; Merino, Esperanza
title: Medium‐term serostatus in Spanish case series recovered from SARS‐CoV‐2 infection
date: 2021-06-24
journal: J Med Virol
DOI: 10.1002/jmv.27135
sha: fa7538b95093a15af75b19d1a4ba672d60a14edb
doc_id: 920637
cord_uid: zywl1nnj

The medium‐term serologic response of SARS‐CoV‐2 infection recovered individuals is not well known. The aims were to quantify the incidence of seropositive failure in the medium term in a cohort of patients with different COVID‐19 severity and to analyze its associated factors. Patients who had recovered from mild and severe forms of SARS‐CoV‐2 infection in an Academic Spanish hospital (March 12–May 2, 2020), were tested for total anti‐SARS‐CoV‐2 antibodies by electrochemiluminescence immunoassay (Elecsys Anti‐SARS‐CoV‐2 test; Roche Diagnostics GmbH). The non‐seropositive status (seropositive failure) incidence (95% CI) was determined. Associations were tested by multiple logistic regression in a global cohort and severe pneumonia subpopulation. Of 435 patients with PCR‐confirmed SARS‐CoV‐2, a serological test was carried out in 325: 210 (64.6%) had severe pneumonia (hospitalized patients), 51 (15.7%) non‐severe pneumonia (managed as outpatients), and 64 (19.7%) mild cases without pneumonia. After a median (IQR) of 76 days (70–83) from symptom onset, antibody responses may not consistently develop or reach levels sufficient to be detectable by antibody tests (non‐seropositive incidence) in 6.9% (95% CI, 4.4–10.6) and 20.3% (95% CI, 12.2–31.7) of patients with and without pneumonia, respectively. Baseline independent predictors of seropositive failure were higher leukocytes and fewer days of symptoms before admission, while low glomerular filtrate and fever seem associated with serologic response. Age, comorbidity or immunosuppressive therapies (corticosteroids, tocilizumab) did not influence antibody response. In the medium‐term, SARS‐CoV‐2 seropositive failure is not infrequent in COVID‐19 recovered patients. Age, comorbidity or immunosuppressive therapies did not influence antibody response.

by antibody tests (non-seropositive incidence) in 6.9% (95% CI, 4.4-10.6) and 20.3% (95% CI, 12.2-31.7) of patients with and without pneumonia, respectively. Baseline independent predictors of seropositive failure were higher leukocytes and fewer days of symptoms before admission, while low glomerular filtrate and fever seem associated with serologic response. Age, comorbidity or immunosuppressive therapies (corticosteroids, tocilizumab) did not influence antibody response. In the medium-term, SARS-CoV-2 seropositive failure is not infrequent in COVID-19 recovered patients. Age, comorbidity or immunosuppressive therapies did not influence antibody response. antibodies about 1 week after symptom onset, persisting for at least 3 months. 1 The duration of antibody rises is currently unknown, and there are scant data on the presence of antibodies in the medium or long term. 2 However, titers of neutralizing antibodies against the SARS-CoV-2 spike protein were detectable for at least 5 months after primary infection. 3 Numerous immunoassays for the detection of antibodies to SARS-CoV-2 are emerging rapidly and have the potential to improve the diagnosis and monitoring of infection in different scenarios.

Challenges arise in terms of sample collection, clinical translation, population studied, and sampling biases. 4, 5 Knowing the seroconversion rate is essential when interpreting seroprevalence studies, due to the implications for understanding the spread of infection at the population level and decision-making in health policy. 6 The objectives of the study were to quantify the incidence of SARS-CoV-2 infection non-seropositive status in the medium term and to analyze the factors associated with the nonproduction of anti-SARS-CoV-2 antibodies in a cohort of patients with COVID-19.

Retrospective cohort study, of patients who had recovered from symptomatic SARS-CoV-2 infection diagnosed in the emergency department by RT-PCR between March 3 to May 2, 2020.

Of 435 patients with PCR-confirmed SARS-CoV-2, a serological study was not carried out or was invalid (carried out less than 14 days after symptoms onset) in 110 patients, so finally, 325 were included in the analysis. Patients were classified into pneumonia (includes severe-hospitalized patients and nonsevere pneumonia (managed on an outpatient basis, hospital follow-up at home)), and mild cases without pneumonia (managed by primary care physician). The diagnosis of pneumonia required the demonstration of opacity on chest imaging (chest x-ray) in a patient with a clinically compatible syndrome; if lung involvement was suspected based on clinical features despite a negative chest radiograph, we obtained a computed tomography. The criteria for non-severe pneumonia included mild unilobar or multilobar alveolar pneumonia (radiological opacities < 50% pulmonary area) without dyspnea, sat02 ≥ 95% (Fi02 0.21), PaO 2 :FiO 2 > 300 and a respiratory rate <20 rpm, normal glutamic oxaloacetic transaminase (GOT)/glutamic pyruvic transaminase (GPT) and lactate dehydrogenase (LDH), D-dimer < 1000 ng/ml, lymphocyte count > 1200 mm 3 , and a normal 50 meters walking test (pulse oximetry saturation: desaturation < 5 points, and > 93%). Patients without serology, excluded from the analysis, did not differ in severity from the study population.

The main outcome was non-seropositive status at the time of evaluation: anti-SARS-CoV-2 antibody responses may not consistently develop or reach levels sufficient to be detectable by antibody tests. Blood samples were analyzed by electrochemiluminescence immunoassay (ECLIA) (Elecsys Anti-SARS-CoV-2 test, Roche Diagnostics GmbH) to detect total antibodies anti-SARS-CoV-2 including IgG, using a recombinant protein which represents the nucleocapsid antigen (N), the most sensitive target for serological diagnosis of infection with SARS-CoV-2. [7] [8] [9] The test was high-throughput and had a short turnaround time, being suitable for routine care settings. The sensitivity of this test was 96.8% ≥14 days after PCR-positivity and specificity of 99%. 10 The non-seropositive status incidence (95% CI) at the time of evaluation was determined. Multiple logistic regression models were built to explore which risk factors present at diagnosis were Table 1 shows the associations between negative serostatus and explanatory variables. In the univariate analysis, age, comorbidity, and the absence of pneumonia were associated with a lower frequency of antibody detection, this association was lost after adjusting for confounding factors.

After adjustment (Figure 1 ), in the global cohort baseline, independent predictors of seropositive failure were higher leukocytes and fewer days of symptoms (<3 days) before clinical evaluation.

In the severe pneumonia subpopulation, higher leukocytes and fewer days of symptoms (<4) before admission, remained as a risk factor for seropositive failure.

The present study showed that the non-seropositive incidence eleven weeks after disease onset varies according to the clinical severity, being threefold higher in mild cases. Neither age, comorbidity, nor the use of immunosuppressive drugs had an impact on the seropositive rate. However, the impact on the immune response of higher leukocytes and fewer days of symptoms before admission will need to be confirmed in future studies as at this time the relationship between seropositivity and leukocyte counts or with a lower number of days with symptoms before admission has not been described in other studies. 11 Small sample sizes and short follow-up post-symptom onset (limited to 60-65 days follow-up), constitute the main limitations of the available evidence, about the immune response to SARS-CoV-2 infections. 11 In hospitalized patients, published seroconversion rates range from 85% to 100%. 12 Liu et al. 13 Our study has some limitations. This is an observational, retrospective, single-center study, and the collection of data was not standardized in advance. Also, we did not include asymptomatic in- Severe pneumonia subpopulation numbers and percentages of patients with each risk factor who non-seroconverted (risk factor present) and of patients without each risk factor who seroconverted (risk factor absent) are shown. Variables were included as covariates if they showed significant associations in simple models. The 95% CIs of the odds ratios have been adjusted for multiple testing. R2 models for non-seroconversion: 0.50, global cohort; 0.47, severe pneumonia subpopulation. In bold, independent predictors associated with the outcomes. eGFR by CKD-EPI formula; * on admission. For the purpose of logistic regression models in the global cohort and severe pneumonia subpopulation, variables were categorized regarding their 75-percentiles within each subpopulation, to show the impact of severe extreme values in the outcomes-except for those in which severity is defined by lowest levels, such as clinical evolution and lymphocyte counts, where 25-percentiles were used. For the following variables, standard categorizations were followed: age ≥65 years, Charlson comorbidity index ≥3, eGFR <60 ml/min/1.73 m 2 , PaO2:FiO2 < 300. The inclusion of tocilizumab use and anosmia as admission symptom in the logistic regression models (not included in the initial models due to 100% seroconverted), led to renal failure in global cohort and fever in the severe pneumonia subpopulation, reaching statistical significance as protective factors. CI, confidence interval; eGFR, estimated glomerular filtration rate whether the non-seroconversion rates in patients with infections of varying severity were due to lack of antibody activation, with lowlevel N protein expression and N antibodies production, or to their rapid decline.

In summary, this experience provides a large case series at a community level that evaluates the incidence of seropositive failure, according to the clinical spectrum produced by the SARS-CoV-2 infection. 

Spread of SARS-CoV-2 in the Icelandic population

Antibody tests for identification of current and past infection with SARS-CoV-2

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

What policy makers need to know about COVID-19 protective immunity

Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France

Seroprevalence of SARS-CoV-2 antibodies in over 6000 healthcare workers in Spain

Sensitivity of anti-SARS-CoV-2 serological assays in a high-prevalence setting

Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites

Comparison of the clinical performance and usefulness of five SARS-CoV-2 antibody tests

Serodiagnostics for severe acute respiratory syndrome-related coronavirus-2: a narrative review

Immune response following infection with SARS-CoV-2 and other coronaviruses: a rapid review

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

Antibody profiles in mild and severe cases of COVID-19

Antibody responses after COVID-19 infection in patients who are mildly symptomatic or asymptomatic in Bangladesh

Comparison of the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based antibody tests

COVID-19: immunopathology and its implications for therapy

COVID-19 diagnosis-a review of current methods

Natural mucosal barriers and COVID-19 in children

Specificity testing by point prevalence as a simple assessment strategy using the Roche Elecsys® Anti-SARS-CoV-2 immunoassay

The data sets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Written informed consent was obtained from all the participants, with approval by the institutional review board (EXP. 200145).